XKRX047920
Market cap447mUSD
Dec 26, Last price
22,200.00KRW
1D
2.54%
1Q
-14.94%
Jan 2017
327.75%
IPO
189.57%
Name
HLB Pharmaceutical Co Ltd
Chart & Performance
P/E
—
P/S
4.83
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.59%
Rev. gr., 5y
45.93%
Revenues
135.95b
+26.49%
Net income
-19.43b
L+64.96%
CFO
-18.32b
L+562.97%
Profile
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju-Si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 135,952,754 26.49% | 107,481,872 71.01% | 62,852,784 54.92% | |||||
Cost of revenue | 148,501,958 | 109,075,722 | 58,456,988 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (12,549,204) | (1,593,850) | 4,395,795 | |||||
NOPBT Margin | 6.99% | |||||||
Operating Taxes | 576,061 | 824,931 | 408,141 | |||||
Tax Rate | 9.28% | |||||||
NOPAT | (13,125,264) | (2,418,781) | 3,987,654 | |||||
Net income | (19,427,453) 64.96% | (11,776,740) -10.96% | (13,225,622) -82.33% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 363,579 | |||||||
BB yield | -0.08% | |||||||
| Debt | ||||||||
Debt current | 22,738,812 | 24,695,129 | 30,867,002 | |||||
Long-term debt | 2,956,324 | 3,311,629 | 4,278,050 | |||||
Deferred revenue | 4 | |||||||
Other long-term liabilities | 1,598,813 | 1,106,114 | 1,601,436 | |||||
Net debt | (21,371,656) | (24,259,891) | (10,018,064) | |||||
| Cash flow | ||||||||
Cash from operating activities | (18,317,424) | (2,762,924) | (1,321,335) | |||||
CAPEX | (4,255,344) | (2,900,617) | (49,511,043) | |||||
Cash from investing activities | 9,581,643 | (13,280,764) | (15,756,578) | |||||
Cash from financing activities | 3,757,723 | 19,148,461 | 9,634,195 | |||||
FCF | (16,373,780) | 3,666,176 | (52,345,811) | |||||
| Balance | ||||||||
Cash | 31,374,368 | 24,244,375 | 25,544,602 | |||||
Long term investments | 15,692,424 | 28,022,274 | 19,618,514 | |||||
Excess cash | 40,269,154 | 46,892,555 | 42,020,477 | |||||
Stockholders' equity | (9,275,451) | 24,993,381 | (44,490,543) | |||||
Invested Capital | 122,755,232 | 88,392,231 | 157,345,401 | |||||
ROIC | 3.26% | |||||||
ROCE | 3.90% | |||||||
| EV | ||||||||
Common stock shares outstanding | 29,168 | 27,323 | 23,072 | |||||
Price | 15,210.00 43.49% | 10,600.00 -21.48% | 13,500.00 -21.05% | |||||
Market cap | 443,649,006 53.18% | 289,622,761 -7.01% | 311,467,356 15.53% | |||||
EV | 422,277,350 | 265,362,870 | 301,449,292 | |||||
EBITDA | (7,503,437) | 2,941,476 | 8,187,466 | |||||
EV/EBITDA | 90.21 | 36.82 | ||||||
Interest | 11,767,368 | 5,022,596 | 15,878,600 | |||||
Interest/NOPBT | 361.22% | |||||||